CDK4 and neoplasm: Also, given the results of the CDK4/6 inhibitors in combination with fulvestrant in the trials PALOMA-3, MONALEESA-3, and MONARCH 2 for median progression-free survival (HR 0.46,0.60,0.55, respectively), three drugs were approved for use in combination with fulvestrant in patients with tumor progression after first-line endocrine therapy (14–16).